The efficacy and treatment-related adverse events of vedotinumab combined with programmed death-1 inhibitors in the treatment of urothelial carcinoma
10.3969/j.issn.1009-8291.2025.10.003
- VernacularTitle:维迪西妥单抗联合程序性死亡受体1抑制剂治疗尿路上皮癌的效果及不良反应分析
- Author:
Yichuan WANG
1
;
Xiaoyu YI
;
Lei YANG
;
Wei YU
;
Han HAO
Author Information
1. 北京大学第一医院泌尿外科,北京大学泌尿外科研究所,国家泌尿、男性生殖系肿瘤研究中心,北京 100034
- Publication Type:Journal Article
- Keywords:
vedotinumab;
programmed cell death 1 inhibitors;
urothelial carcinoma;
gemcitabine;
cisplatin;
neoadjuvant chemotherapy;
antibody-drug conjugates
- From:
Journal of Modern Urology
2025;30(10):828-832
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of the antibody-drug conjugate(ADC)vedotinumab combined with programmed cell death protein 1(PD-1)inhibitors as neoadjuvant therapy in patients with bladder cancer.Methods This retrospective study included 54 patients with bladder cancer who underwent neoadjuvant therapy at the Department of Urology,Peking University First Hospital,between Jun.2023 and Jun.2025.Among them,26 patients received vedotinumab combined with a PD-1 inhibitors,and 28 patients received gemcitabine plus cisplatin(GC).Clinical data,pathological complete response(pCR)rates,and pathological downstaging rates were collected.Treatment-related adverse events(TRAEs)were also assessed in both groups.Results There were no statistically significant differences between the two groups in terms of age,sex,smoking history,tumor grade and stage,depth of invasion,or human epidermal growth factor receptor 2(HER2)expression,indicating good baseline comparability(P＞0.05).The pCR rate in the vedotinumab plus PD-1 inhibitor group was 57.69％(15/26),significantly higher than that of the GC group at 25.00％(7/28)(P＜0.05).Pathological downstaging occurred in 5 patients in either group,with no statistically significant difference(P＞0.05).The main TRAEs in the vedotinumab plus PD-1 inhibitor group were peripheral sensory neuropathy and rash,and no grade 3-4 severe adverse events were observed.In contrast,the GC group predominantly experienced bone marrow suppression,with 4 cases of grade 3-4 adverse events.Conclusion Vedotinumab combined with PD-1 inhibitors demonstrated significantly superior efficacy and favorable safety compared with the conventional GC regimen as neoadjuvant therapy for bladder cancer.
